Malaysian Genomics Resource Centre Bhd. Stock Analysis MGRC.KL

Malaysian Genomics Resource Centre Bhd. The company is headquartered in Petaling Jaya, Selangor and currently employs 35 full-time employees. The company went IPO on 2010-01-25. The firm is engaged in enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. Its services include Genome Sequencing Services, Genome Analysis Services, Genetic Screening Services, and Cancer Immunotherapy. Its whole genome sequencing (WGS) is a comprehensive technique used to determine the complete deoxyribonucleic acid (DNA) sequence of an individual’s entire genome. Its flagship product, the Dtect genetic screening tests, inspects an individual’s DNA for markers associated with genetic variations that influence various biological processes. Its CAR T-cell immunotherapy focuses on the immune system’s ability to detect and eliminate cancer cells. Its Genome analysis includes services, such as bioinformatics, trait analysis, and trio sequencing.